Photo by impulsq from unsplash
Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2 Day 1, 5‐FU 2400 mg/m2 × 48 h IV, peg‐filgrastim 6 mg SQ day 3,… Click to show full abstract
Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2 Day 1, 5‐FU 2400 mg/m2 × 48 h IV, peg‐filgrastim 6 mg SQ day 3, every 14 days) has substantial activity in metastatic PDAC. We wished to determine the tolerability/efficacy of peri‐operative mFOLFIRINOX in resectable PDAC.
Keywords:
systemic therapy;
resectable pancreatic;
primary systemic;
mfolfirinox;
therapy resectable
Journal Title: Journal of Surgical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Surgical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!